Actively Recruiting
Evaluation of the Anti-VZV Vaccine Response of Patients With Immune-mediated Systemic Inflammatory Diseases Vaccinated in the Care Setting
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-07-02
50
Participants Needed
1
Research Sites
94 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with immune-mediated systemic inflammatory diseases (IMID) are at increased risk of shingles due to treatment-induced immunosuppression. In line with international recommendations, the French National Authority for Health (HAS) updated the varicella-zoster virus (VZV) vaccination strategy in March 2024. The HAS now recommends that immunocompromised people aged 18 and over be vaccinated with the recombinant VZV vaccine. However, due to the immunosuppressive treatment received, the vaccine response in MIMI patients is often suboptimal, and the protection induced by the herpes zoster vaccine in this context is unknown. The aim of our study is to determine the rate of anti-VZV seroconversion after vaccination with recombinant anti-VZV vaccine, in patients followed up for MIMI.
CONDITIONS
Official Title
Evaluation of the Anti-VZV Vaccine Response of Patients With Immune-mediated Systemic Inflammatory Diseases Vaccinated in the Care Setting
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years of age being managed for immune-mediated systemic inflammatory diseases (IMID), including systemic lupus, Gougerot-Sjögren's syndrome, systemic scleroderma, mixed connectivitis, inflammatory myositis, systemic sarcoidosis, systemic vasculitis (necrotizing vasculitis and giant cell arteritis), Behçet's disease, adult Still's disease, IgG4-associated disease, autoimmune cytopenias, Susac syndrome
- Followed in the internal medicine department of Hôpital Bichat, Paris
- Justifying VZV vaccination due to immunosuppression or age over 65
- Vaccinated as part of care between June 2025 and June 2026
- Regardless of history of shingles
- With a serum sample available for analysis
- Having received at least the first dose of the vaccine regimen (in hospital or in the community)
You will not qualify if you...
- Evolving cancer, with or without treatment (chemotherapy, immunotherapy, etc.)
- History of VZV vaccination (live or recombinant)
- Patient who has had an allergic reaction to a vaccine
- Pregnancy
- Patient under legal protection, guardianship or trusteeship
- Not affiliated to a social security scheme (general or CMU)
- Patient unable to understand research information
- Absence of non-opposition
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Bichat
Paris, France, 75018
Actively Recruiting
Research Team
T
Tiphaine Goulenok, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here